Calciphylaxis: a systematic review of existing and emerging therapies.
| Autor: | Vedvyas C; Harvard Medical School, Boston, Massachusetts 02115, USA. chetan@post.harvard.edu, Winterfield LS, Vleugels RA |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2012 Dec; Vol. 67 (6), pp. e253-60. Date of Electronic Publication: 2011 Aug 06. |
| DOI: | 10.1016/j.jaad.2011.06.009 |
| Abstrakt: | Calciphylaxis, also known as calcific uremic arteriolopathy, is a cutaneous ischemic small vessel vasculopathy seen in 1 to 4% of patients with chronic kidney disease on hemodialysis. It is associated with extreme pain and a 60 to 80% mortality rate in the setting of few and frequently ineffective therapeutic options, although this may be changing based on reports of success with newer therapies. (Copyright © 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect